ProFibrix, B.V.: Series B $10.6M

Posted in I - Series B, Q - 2Q11, R - INTERNATIONAL, X - Fibrinogen, X - Hemostasis

ProFibrix (Netherlands) a clinical-stage company focused on blood clotting and tissue healting, closed a $10.6M Series B financing, bringing the total round to $21.6M. Participants include Gilde Healthcare Partners and Index Ventures.

Oct

2009

ProFibrix, BV: Series B $11M

Posted in I - Series B, Q - 3Q09, R - INTERNATIONAL, X - Fibrinogen, X - Hemostasis

ProFibrix (Netherlands) a clinical-stage company focused on fibrinogen for use in homeostasis and regenerative medicine, closed a $11M Series B financing. Participants include Gilde Healthcare Partners and Index Ventures.

Jun

2009

LifeBond, Ltd.: Series B $8M

Posted in I - Series B, Q - 2Q09, R - INTERNATIONAL, X - Biomaterial, X - Hemostasis, X - Wound Healing

LifeBond (Israel) a commercial-stage developer of wound-closure and hemostasis biomaterials, closed a $8M Series B financing. Participants include Pitango Venture Capital, GlenRock Israel and The Zitelman Group.

to top of page...